Pharmaceutical industry – Page 28
-
BusinessLonza to buy capsule manufacturer in $5.5bn deal
Swiss pharma firm looks to strengthen its position as world’s biggest drug manufacturing subcontractor
-
BusinessUS pharma executives face bribery charges over opioid painkiller prescriptions
Insys Therapeutics chief executive and senior managers accused of running a conspiracy to bribe doctors across several states
-
BusinessBristol-Myers Squibb planning huge reorganisation in the US
Job losses likely as Hopewell, New Jersey site will close by 2020
-
CareersCatching up with AstraZeneca's graduate programme
Three years on, Manisha Lalloo revisits the pharma giant’s training scheme
-
BusinessPharmaceutical industry roundup of 2016
Controversial approvals and price clashes characterised 2016 in pharma
-
BusinessEndo drops opioid painkiller rights and cuts US sales force
375 staff to go as Endo says its established pain drugs ‘no longer require field promotion’
-
BusinessBoehringer Ingelheim sheds more jobs in the US
Over 240 staff to go as company refocuses on immuno-oncology
-
-
Business£90m fine for Pfizer and Flynn Pharma over excessive drug pricing
Markets watchdog imposes record fine for breaches of competition law
-
BusinessPfizer pulls back on UK and Ireland facilities
€400 million manufacturing plant expansion cancelled and two facilities to close
-
BusinessFormer Valeant and Philidor executives arrested for fraud
Prosecutors allege the men masterminded a kickback scheme between Valeant and the speciality pharmacy
-
OpinionHow much does fashion influence chemists?
Is that new reaction the next Nobel-worthy breakthrough, or just a flash in the pan?
-
OpinionRestarting the mental health pipeline
The lack of UK investment in new drugs for mental health disorders is a problem – but the tide may be about to turn
-
CareersThe trials and tribulations of drug discovery
The many pitfalls medicinal chemists face when creating a new drug
-
FeaturePersonalised skincare
Nina Notman explores some of the latest scientific approaches skincare companies are using in the quest to develop high-earning anti-ageing cosmetics
-
OpinionRegulatory tightropes
When lobbying and marketing clash with scientific evidence, regulators walk a fine line
-
OpinionPutting chemistry back in biology
The chemical nature of biomolecular interactions can no longer be ignored
-
BusinessA match made in medicine
Technology companies have begun to turn their resources towards health research. Is it just hype or can big tech bring something new?
-
BusinessAstraZeneca sheds multiple drugs
Spate of licensing deals for non-core products as firm further tightens R&D focus
-
NewsPfizer launches new biosimilar drug in US
Autoimmune disease treatment becomes only the second biosimilar to be approved by the FDA